Profil Institute is proud to support the clinical research and development activities of Hanmi Pharmaceuticals and congratulate Hanmi and Sanofi on their partnership to develop therapeutics addressing diabetes.
The licensing agreement announced by Sanofi and Hanmi Pharmaceuticals represents the intent to develop and commercialize Hanmi’s portfolio of three long-acting GLP-1 agonist and basal insulin candidates, including efpeglenatide, a phase 2b GLP-1 agonist with the potential for once-weekly to once-monthly dosing; LAPSInsulin-115, a phase 1 once-weekly insulin; and LAPSInsulin Combo, a preclinical once-weekly fixed-ratio GLP-1 agonist/basal insulin combination of efpeglenatide and LAPSInsulin-115. The three candidates were developed using Hanmi’s proprietary LAPSCOVERY technology.
According to the press release, Sanofi will provide Hanmi with an upfront payment of €400 million (~$434 million). Hanmi will also be eligible for up to €3.5 billion (~$3.8 billion) based on development, registration, and sales milestones and will earn double-digit royalties on net sales of the products. While Sanofi gains worldwide commercialization rights, Hanmi will retain an exclusive option to co-commercialize the products in South Korea and China.
Profil Institute and Hanmi have jointly presented data at the American Diabetes Association (ADA) Scientific Sessions and European Association for the Study of Diabetes (EASD) Annual Meetings since 2013. Below are links to abstracts related to the three long-acting GLP-1 agonist and basal insulin candidates and presented at the most recent ADA Scientific Sessions.